Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (Jul 2016)

Circulating N‐Linked Glycoprotein Side‐Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial

  • Akintunde O. Akinkuolie,
  • Robert J. Glynn,
  • Latha Padmanabhan,
  • Paul M Ridker,
  • Samia Mora

DOI
https://doi.org/10.1161/JAHA.116.003822
Journal volume & issue
Vol. 5, no. 7

Abstract

Read online

BackgroundGlycA, a novel protein glycan biomarker of N‐acetyl side chains of acute‐phase proteins, was recently associated with incident cardiovascular disease (CVD) in healthy women. Whether GlycA predicts CVD events in the setting of statin therapy in men and women without CVD but with evidence of chronic inflammation is unknown. Methods and ResultsIn the Justfication for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial (NCT00239681), participants with low‐density lipoprotein cholesterol 0.20). ConclusionIn the JUPITER trial, increased levels of GlycA were associated with an increased risk of CVD events independent of traditional risk factors and hsCRP. Clinical Trials RegistrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681.

Keywords